Clinical Trial Update: A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of INCB050465 in relapsed or refractory follicular lymphoma has completed, with results posted. The sponsor is Incyte Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• INCB050465

Snippet

Sponsor: Incyte Corporation | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-10